Proof-of-concept results show crofelemer reduced total parenteral nutrition in patients with rare diseases microvillus inclusion disease (mvid) and short bowel syndrome with intestinal failure (sbs-if) by up to 27% and 12.5% - potential to modify disease progression in intestinal failure patients

Jaguar to host investor webcast today at 8:30 am eastern to review the initial results from the proof-of-concept study of crofelemer for mvid and sbs-if presented april 26 at the annual elite ped-gi congress ; click here to register there are no approved drug treatments for mvid, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management including total parenteral nutrition (tpn) - which carries the risk of morbidity, infections, metabolic complications, liver and kidney problems, and neurodevelopmental delay this proof-of-concept data in mvid supports crofelemer's potential inclusion in the european medicines agency's (ema) prime program for expediated and assisted regulatory approval in the eu as well as fda's breakthrough therapies program for expedited regulatory approval in the us san francisco, ca / access newswire / april 30, 2025 / jaguar health, inc. (nasdaq:jagx) (jaguar) family companies napo pharmaceuticals (napo) and napo therapeutics today announced initial proof-of-concept results showing that a novel liquid formulation of crofelemer reduced the required tpn and/or supplementary intravenous fluids, collectively referred to as parenteral support (ps) in patients with intestinal failure due to microvillus inclusion disease (mvid) and short bowel syndrome (sbs-if) by up to 27% and 12.5% respectively. in addition, this data showed that crofelemer reduced stool volume output and/or frequency of watery stools, and increased urine output - an indicator of improved nutrient oral absorption.
SBS Ratings Summary
SBS Quant Ranking